Endo International plc's subsidiary Paladin Labs Inc. has launched Travelan, a unique over-the-counter product to help reduce the risk of travellers’ diarrhoea.
Travelan is clinically proven to provide protection against the main cause of travellers’ diarrhoea in 90 per cent of consumers who use it. Travelan is a convenient option for all those travelling to at-risk regions such as Central and South America, Mexico, Africa, the Middle East and Asia. It does not require a prescription, and is not associated with any significant side effects.
It is estimated that there are over 5 million trips made by Canadians to at-risk regions every year. One-in-three Canadian vacationers have experienced, or have travelled with someone who has experienced, travellers' diarrhoea. Sources of Enterotoxigenic Escherichia Coli (ETEC) bacteria, which cause the majority of cases of travellers' diarrhoea, can include poorly cooked meat, contaminated raw vegetables or unpasteurized dairy products. Given that no food group can be regarded as "safe"4, research demonstrates that three-quarters of Canadians have indicated that they would take a preventive for travellers’ diarrhoea.
"We are pleased to announce the launch of Travelan in Canada," said Mark Beaudet, president of Paladin Labs Inc. "This option responds to the clear market need for a clinically proven, accessible option to help reduce the risk of travellers’ diarrhoea."
Paladin obtained the exclusive rights to market and sell Travelan in Canada, Latin America (including Brazil and Mexico) and Sub-Saharan Africa (including South Africa) from Immuron Ltd in November 2011.
Travelan is a natural product which is specifically designed to reduce the risk of infection by ETEC, the most common cause of travellers' diarrhoea. In clinical trials, Travelan showed efficacy of up to 90 per cent in protecting against infection with the type of E.Coli that causes travellers' diarrhoea. In addition, trials showed a significant reduction in abdominal cramps and stomach pain compared to those who did not receive Travelan. There were no reported treatment-related side effects in the clinical trials.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.